Menu Search
Equities

Solution Group Bhd

SOLUTN:KLS

Solution Group Bhd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (MYR)0.135
  • Today's Change0.01 / 8.00%
  • Shares traded175.40k
  • 1 Year change-43.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in MYRIncome statement in MYRView more

Year on year Solution Group Bhd grew revenues 264.21% from 33.20m to 120.93m while net income improved from a loss of 39.73m to a gain of 163.87k.
Gross margin11.32%
Net profit margin1.80%
Operating margin3.70%
Return on assets2.25%
Return on equity1.10%
Return on investment3.27%
More ▼

Cash flow in MYRView more

In 2023, Solution Group Bhd increased its cash reserves by 128.42%, or 7.90m. Cash Flow from Financing totalled 9.71m or 8.03% of revenues. In addition the company used 1.63m for operations while cash used for investing totalled 196.76k.
Cash flow per share0.0128
Price/Cash flow per share11.17
Book value per share0.1643
Tangible book value per share0.1642
More ▼

Balance sheet in MYRView more

Solution Group Bhd has a Debt to Total Capital ratio of 14.83%, a higher figure than the previous year's 8.21%.
Current ratio2.45
Quick ratio2.38
Total debt/total equity0.186
Total debt/total capital0.1483
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.